|

IMA203 Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: anzu-cel, anzutresgene autoleucel

Pipeline

Phase 1: 1Phase 3: 1

Top Sponsors

  • Immatics US, Inc.2

Indications

  • Cancer2
  • Melanoma, Cutaneous Malignant1
  • Synovial Sarcoma1
  • Cutaneous Melanoma1

Phoenix, Arizona1 trial

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Mayo Clinic

Phase 3

San Francisco, California1 trial

ACTengine® IMA203 Combined With mRNA-4203

University of California San Francisco

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.